Related references
Note: Only part of the references are listed.Combining ibrutinib and checkpoint blockade improves CD8+ T-cell function and control of chronic lymphocytic leukemia in Eμ-TCL1 mice
Bola S. Hanna et al.
HAEMATOLOGICA (2021)
Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1 /PD-1 immunotherapy
Nikolaos Ioannou et al.
BLOOD (2021)
Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia
Carsten U. Niemann et al.
BLOOD (2021)
Venetoclax Increases Intratumoral Effector T Cells and Antitumor Efficacy in Combination with Immune Checkpoint Blockade
Frederick J. Kohlhapp et al.
CANCER DISCOVERY (2021)
Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia
Michelle J. Cox et al.
MOLECULAR THERAPY (2021)
Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure
Jordan Gauthier et al.
BLOOD (2020)
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial
Jeff P Sharman et al.
LANCET (2020)
T-cells in chronic lymphocytic leukemia: Guardians or drivers of disease?
Philipp M. Roessner et al.
LEUKEMIA (2020)
Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell Lymphomas
Bhawana George et al.
CANCERS (2020)
Real-world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib
Kathrine Aarup et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2020)
Targeting CD38 is lethal to Breg-like chronic lymphocytic leukemia cells and Tregs, but restores CD8+ T-cell responses
Alak Manna et al.
BLOOD ADVANCES (2020)
The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells
Kamira Maharaj et al.
BLOOD ADVANCES (2020)
Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia
Isabelle G. Solman et al.
LEUKEMIA RESEARCH (2020)
Importance of Crosstalk Between Chronic Lymphocytic Leukemia Cells and the Stromal Microenvironment: Direct Contact, Soluble Factors, and Extracellular Vesicles
Nathan Dubois et al.
FRONTIERS IN ONCOLOGY (2020)
Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity
Johannes Sam et al.
FRONTIERS IN ONCOLOGY (2020)
Idelalisib for optimized CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients
Sophia Stock et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables
Andrew W. Roberts et al.
BLOOD (2019)
Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment
Michael Hallek
AMERICAN JOURNAL OF HEMATOLOGY (2019)
The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma
Yi-Xin Zou et al.
HEMATOLOGICAL ONCOLOGY (2019)
Ibrutinib Treatment in CLL Patients Improves T Cell Function and Blinatumomab Redirected Cytotoxicity
Meixiao Long et al.
BLOOD (2019)
Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia
Jan A. Burger et al.
BLOOD (2019)
Rapid Undetectable MRD (uMRD) Responses in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed CAR T Cell Product: Updated Results from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib
Tanya Siddiqi et al.
BLOOD (2019)
Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Initial Results from Arm C of the Sequoia (BGB-3111-304) Trial
Constantine S. Tam et al.
BLOOD (2019)
PI3Kδ inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia
Bola S. Hanna et al.
LEUKEMIA (2019)
Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study
Anas Younes et al.
LANCET HAEMATOLOGY (2019)
Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib
Emily M. McWilliams et al.
BLOOD ADVANCES (2019)
A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL
Anthony R. Mato et al.
BLOOD ADVANCES (2019)
Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment
Iris de Weerdt et al.
BLOOD ADVANCES (2019)
Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia
Marina Wierz et al.
BLOOD (2018)
A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era
Hannah R. Robinson et al.
BLOOD (2018)
The rise of apoptosis: targeting apoptosis in hematologic malignancies
Rebecca Valentin et al.
BLOOD (2018)
BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism
Jiaji G. Chen et al.
BLOOD (2018)
Autologous T-cell activation fosters ABT-199 resistance in chronic lymphocytic leukemia: rationale for a combined therapy with SYK inhibitors and anti-CD20 monoclonal antibodies
Esteban Enrique Elias et al.
HAEMATOLOGICA (2018)
Chronic Lymphocytic Leukemia-Derived IL-10 Suppresses Antitumor Immunity
Sara S. Alhakeem et al.
JOURNAL OF IMMUNOLOGY (2018)
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
Joseph A. Fraietta et al.
NATURE MEDICINE (2018)
Idelalisib impairs TREM-1 mediated neutrophil inflammatory responses
Astrid Alflen et al.
SCIENTIFIC REPORTS (2018)
Autologous T-cell activation fosters ABT-199 resistance in chronic lymphocytic leukemia: rationale for a combined therapy with SYK inhibitors and anti-CD20 monoclonal antibodies
Esteban Enrique Elias et al.
HAEMATOLOGICA (2018)
Improving CLL V gamma 9V delta 2-T-cell fitness for cellular therapy by ex vivo activation and ibrutinib
Iris de Weerdt et al.
BLOOD (2018)
Activation of Th1 Immunity within the Tumor Microenvironment Is Associated with Clinical Response to Lenalidomide in Chronic Lymphocytic Leukemia
Georg Aue et al.
JOURNAL OF IMMUNOLOGY (2018)
Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences
Xinyu Yan et al.
FRONTIERS IN PHARMACOLOGY (2018)
Durable Clinical Responses and Long-Term Follow-Up of Stage III-IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Study - A Brief Research Report
Julie Westerlin Kjeldsen et al.
FRONTIERS IN IMMUNOLOGY (2018)
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
Ian W. Flinn et al.
BLOOD (2018)
Ibrutinib Increases the Clonality of TCR Repertoire in Patients with Chronic Lymphocytic Leukemia
Maria Joao Baptista et al.
BLOOD (2018)
Ibrutinib-Based Therapy Improves Anti-Tumor T Cell Killing Function Allowing Effective Pairing with Anti-PD-L1 Immunotherapy Compared to Traditional FCR Chemoimmunotherapy; Implications for Therapy and Correlative Immune Functional Data from the Phase III E1912 Trial
Despoina Papazoglou et al.
BLOOD (2018)
Targeting B cell receptor signalling in cancer: preclinical and clinical advances
Jan A. Burger et al.
NATURE REVIEWS CANCER (2018)
The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia
Sarah E. M. Herman et al.
CLINICAL CANCER RESEARCH (2017)
T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers
Marzia Palma et al.
HAEMATOLOGICA (2017)
Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199)
V. M. Patel et al.
LEUKEMIA (2017)
T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers
Marzia Palma et al.
HAEMATOLOGICA (2017)
CD40 signaling instructs chronic lymphocytic leukemia cells to attract monocytes via the CCR2 axis
Martijn H. A. van Attekum et al.
HAEMATOLOGICA (2017)
Ibrutinib treatment improves T cell number and function in CLL patients
Meixiao Long et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF06747143) in chronic lymphocytic leukemia
Manoj K. Kashyap et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia
Qingsong Yin et al.
JOURNAL OF IMMUNOLOGY (2017)
Changes in T-cell subpopulations and cytokine network during early period of ibrutinib therapy in chronic lymphocytic leukemia patients: the significant decrease in T regulatory cells number
Monika Podhorecka et al.
ONCOTARGET (2017)
The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages
Lingyan Ping et al.
ONCOTARGET (2017)
CD40 signaling instructs chronic lymphocytic leukemia cells to attract monocytes via the CCR2 axis
Martijn H. A. van Attekum et al.
HAEMATOLOGICA (2017)
Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study
Anna Maria Fink et al.
LANCET HAEMATOLOGY (2017)
Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL
Wei Ding et al.
BLOOD (2017)
Anti-PD-L1 Efficacy Can Be Enhanced by Inhibition of Myeloid-Derived Suppressor Cells with a Selective Inhibitor of PI3Kδ/γ
Ruth J. Davis et al.
CANCER RESEARCH (2017)
Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib - Findings from an Investigator-Initiated Phase II Study
Carsten U. Niemann et al.
CLINICAL CANCER RESEARCH (2016)
Extracellular vesicles released by CD40/IL-4-stimulated CLL cells confer altered functional properties to CD4+ T cells
Dawn T. Smallwood et al.
BLOOD (2016)
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
Joseph A. Fraietta et al.
BLOOD (2016)
Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment
Andrew Stiff et al.
CANCER RESEARCH (2016)
Lenalidomide Induces Interleukin-21 Production by T Cells and Enhances IL21-Mediated Cytotoxicity in Chronic Lymphocytic Leukemia B Cells
Rebekah L. Browning et al.
CANCER IMMUNOLOGY RESEARCH (2016)
PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia
Fabienne McClanahan et al.
BLOOD (2015)
A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia
Susan M. O'Brien et al.
BLOOD (2015)
Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib
Clare Sun et al.
BLOOD (2015)
Treatment with Ibrutinib Inhibits BTK- and VLA-4-Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo
Sarah E. M. Herman et al.
CLINICAL CANCER RESEARCH (2015)
Resistance to ABT-199 induced by microenvironmental signals in chronic iymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors
Rachel Thijssen et al.
HAEMATOLOGICA (2015)
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
Joel D. Leverson et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Nurse-like cells mediate ibrutinib resistance in chronic lymphocytic leukemia patients
F. Boissard et al.
BLOOD CANCER JOURNAL (2015)
Resistance to ABT-199 induced by microenvironmental signals in chronic iymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors
Rachel Thijssen et al.
HAEMATOLOGICA (2015)
Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia
Stefania Fiorcari et al.
HAEMATOLOGICA (2015)
Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy
Fabio Da Roit et al.
HAEMATOLOGICA (2015)
CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs
Regina Jitschin et al.
BLOOD (2014)
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia
Jennifer R. Brown et al.
BLOOD (2014)
Long-term follow-up of a phase 2 trial of single agent lenalidomidein previously untreated patients with chronic lymphocytic leukaemia
Christine I. Chen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study
S. E. M. Herman et al.
LEUKEMIA (2014)
Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer
Khaled Ali et al.
NATURE (2014)
How the microenvironment wires the natural history of chronic lymphocytic leukemia
Federico Caligaris-Cappio et al.
SEMINARS IN CANCER BIOLOGY (2014)
Lenalidomide and Rituximab in Combination As Initial Treatment of Chronic Lymphocytic Leukemia: Initial Results of a Phase II Study
Philip A. Thompson et al.
BLOOD (2014)
T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production
John C. Riches et al.
BLOOD (2013)
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
Jason A. Dubovsky et al.
BLOOD (2013)
Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide
Alan G. Ramsay et al.
BLOOD (2013)
Circulating microenvironment of CLL: Are nurse-like cells related to tumor-associated macrophages?
Agata A. Filip et al.
BLOOD CELLS MOLECULES AND DISEASES (2013)
CXCL12 is a costimulator for CD4+ T cell activation and proliferation in chronic lymphocytic leukemia patients
Mercedes Borge et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia
Davide Brusa et al.
HAEMATOLOGICA (2013)
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Andrew J. Souers et al.
NATURE MEDICINE (2013)
Downregulation of IL-17-producing T cells is associated with regulatory T cell expansion and disease progression in chronic lymphocytic leukemia
Farhad Jadidi-Niaragh et al.
TUMOR BIOLOGY (2013)
Chronic Lymphocytic Leukemia Cells Are Activated and Proliferate in Response to Specific T Helper Cells
Audun Os et al.
CELL REPORTS (2013)
Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia
Matthew S. Davids et al.
BLOOD (2012)
The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia
Martin F. M. de Rooij et al.
BLOOD (2012)
Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer
Alan G. Ramsay et al.
BLOOD (2012)
Association of an increased frequency of CD14+HLA-DRlo/neg monocytes with decreased time to progression in chronic lymphocytic leukaemia (CLL)
Michael P. Gustafson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Lower Phosphorylation of p38 MAPK Blocks the Oxidative Stress-induced Senescence in Myeloid Leukemic CD34+CD38- Cells
Yin Xiao et al.
JOURNAL OF HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY-MEDICAL SCIENCES (2012)
The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia
Yair Herishanu et al.
BLOOD (2011)
CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
Brian J. Lannutti et al.
BLOOD (2011)
The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia
Julia Hoellenriegel et al.
BLOOD (2011)
Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response
Asher A. Chanan-Khan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia
David L. Porter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
Michael Kalos et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals
Sarah E. M. Herman et al.
BLOOD (2010)
Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
Mark P. Chao et al.
CELL (2010)
Exploration of the Lysis Mechanisms of Leukaemic Blasts by Chimaeric T-Cells
David Laurin et al.
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY (2010)
The microenvironment in mature B-cell malignancies: a target for new treatment strategies
Jan A. Burger et al.
BLOOD (2009)
Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drug
Alan G. Ramsay et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug
Alan G. Ramsay et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Bim/Bcl-2 balance is critical for maintaining naive and memory T cell homeostasis
Sara Wojciechowski et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2007)
Immune defects in patients with chronic lymphocytic leukemia
F Ravandi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1α
M Nishio et al.
BLOOD (2005)
Share Paper
